<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="631">
  <stage>Registered</stage>
  <submitdate>8/08/2005</submitdate>
  <approvaldate>8/08/2005</approvaldate>
  <nctid>NCT00127972</nctid>
  <trial_identification>
    <studytitle>2NN &amp; CHARM Long-Term Follow-up Study</studytitle>
    <scientifictitle>A Retrospective Study to Compare the 3-Year Antiviral Efficacy of Nevirapine and Efavirenz in Combination With D4t and 3tc in 2NN Patients and of Trizivir Versus Trizivir Plus Nevirapine in CHARM Patients</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>04IAT0035</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>HIV Infections</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Acquired immune deficiency syndrome (AIDS / HIV)</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - stavudine
Treatment: drugs - lamivudine
Treatment: drugs - nevirapine
Treatment: drugs - efavirenz
Treatment: drugs - trizivir

Treatment: drugs: stavudine


Treatment: drugs: lamivudine


Treatment: drugs: nevirapine


Treatment: drugs: efavirenz


Treatment: drugs: trizivir


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To determine whether the number of patients with treatment failure after 144 weeks of follow-up is different between study arms</outcome>
      <timepoint />
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To determine whether the percentage of patients with treatment failure after 144 weeks of follow-up is different between the treatment arms</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To determine whether the percentage of patients with virologic failure after 144 weeks of follow-up is different between the treatment arms</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Participation in the original 2NN or CHARM study</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria />
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose />
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate />
    <actualstartdate>1/02/2004</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>763</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/04/2007</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Holdsworth House Medical Practice - Darlinghurst</hospital>
    <postcode>NSW2010 - Darlinghurst</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>International Antiviral Therapy Evaluation Center</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Boehringer Ingelheim</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>It is desirable to obtain extended follow up data on subjects who participated in the 2NN
      study and the CHARM study in order to see if the beneficial effect of using nevirapine
      continues up to 144 weeks of treatment.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00127972</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Joep MA Lange, MD PhD</name>
      <address>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>